Egetis Therapeutics AB (publ) (EGTX) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Egetis Therapeutics Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.457 Welcome to Agedis Therapeutics Q1 Report 2026. 00:00:03.457 -- 00:00:08.705 For the first part of the conference call, the participants will be in listen-only mode. 00:00:08.705 -- 00:00:13.893 During the questions and answers session, participants are able to ask questions by dialing 00:00:13.893 -- 00:00:18.962 pound key 5 on their telephone keypad. If you are listening to the presentation via 00:00:18.962 -- 00:00:22.587 webcast, you can ask written questions using the form below. 00:00:22.587 -- 00:00:26.594 Now I will hand the conference over to CEO Nicholas Westerholm. 00:00:26.594 -- 00:00:29.075 Please go ahead. 00:00:29.613 -- 00:00:34.799 Good morning, and a warm welcome to our quarter one results plan for the coming 00:00:34.799 -- 00:00:39.705 30 minutes. For those who haven't had the privilege to meet before, my name is Nick Rousseff, 00:00:39.705 -- 00:00:45.171 and I'm the CEO of the company. With me today, we also have Yilmaz Mashi, 00:00:45.171 -- 00:00:50.278 Chief Financial Officer, Henrik Lund, Vice President, Commercial Operations, 00:00:50.278 -- 00:00:55.384 Annie Bedard, President of our U.S. business, and Karl Hahn, Vice President 00:00:55.384 -- 00:00:58.245 and Head of Investor Relations. 00:00:59.009 -- 00:01:03.794 Let's turn our attention to the topics covered today, depicted on the slide in front 00:01:03.794 -- 00:01:09.640 of you. To summarize, Quarter 1 has been historical for EGTIS, 00:01:09.640 -- 00:01:15.206 with several key milestones delivered. Amongst others, and most importantly, 00:01:15.206 -- 00:01:20.331 the FDA acceptance of our new drug application for the treatment 00:01:20.331 -- 00:01:23.174 of MCTA deficiency. 00:01:23.174 -- 00:01:28.665 Where the Agency also granted us a priorit...